Related Experiment Video

Updated: Jul 11, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K

Special Issue Editorial: Emerging Therapies in Renal Cell Carcinoma: The Road to a Cure?

Matthew T Campbell1, Tian Zhang2

  • 1Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Cancers
|November 14, 2023
PubMed

Insights

Recent advancements have significantly expanded treatment options for renal cell carcinoma (RCC). This research explores the latest therapeutic strategies and their impact on patient outcomes in kidney cancer.

Area of Science:

  • Oncology
  • Nephrology
  • Translational Medicine

Background:

  • The last 20 years have witnessed a surge in therapeutic development for renal cell carcinoma (RCC).
  • Targeted therapies and immunotherapies have emerged as key treatment modalities.
  • Understanding the evolving landscape of RCC treatment is crucial for improving patient survival rates.

Discussion:

  • Novel therapeutic agents are transforming the management of advanced renal cell carcinoma.
  • The integration of molecular profiling is guiding personalized treatment approaches.
  • Evaluating the efficacy and toxicity of emerging therapies is essential for clinical practice.

Key Insights:

  • Significant progress has been made in developing targeted therapies and immunotherapies for renal cell carcinoma.
  • Biomarker discovery is crucial for predicting treatment response in kidney cancer patients.
  • Multidisciplinary approaches are optimizing care for individuals with renal cell carcinoma.

Outlook:

  • Future research will focus on overcoming therapeutic resistance and enhancing combination strategies.
  • Continued investigation into novel drug targets and predictive biomarkers is warranted.
  • The long-term impact of recent advancements on renal cell carcinoma outcomes requires ongoing evaluation.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.7K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

814

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K